Catherine C. Coombs, MD

Catherine C. Coombs, MD, discusses unmet needs and offers advice for community oncologists treating patients with relapsed/refractory chronic lymphocytic leukemia.

An overview of recent data from ongoing trials evaluating CAR T-cell therapy and BTK inhibitors in patients with relapsed/refractory CLL.

An expert oncologist reviews the MURANO trial of venetoclax plus rituximab in patients with relapsed/refractory CLL and discusses MRD as a parameter of treatment response.

Catherine C. Coombs, MD, reviews currently available treatment options for patients with relapsed/refractory chronic lymphocytic leukemia.

An expert on chronic lymphocytic leukemia discusses disease progression and prognostic factors that influence treatment decisions.

Catherine C. Coombs, MD, presents the case of a 70-year-old man with relapsed/refractory chronic lymphocytic leukemia and offers her initial impressions.

Catherine Coombs, MD, MS, shares her thoughts on the future of treatment and where the field is moving for patients with CLL.

A detailed description of emerging treatment options for patients with relapsed/refractory CLL.

Catherine Coombs, MD, MS, highlights available data and considerations for retreatment with venetoclax in the relapsed/refractory setting.

A comprehensive review of existing second-line treatment options for patients with R/R CLL.

Catherine Coombs, MD, MS, reviews factors that impact the selection of treatment in patients with CLL.

An expert in treating CLL discusses potential treatment options for a patient with relapsed/refractory CLL who has been previously treated with venetoclax plus obinutuzumab.

Catherine Coombs, MD, MS, introduces the case of a patient with relapsed/refractory CLL and shares her impressions on the patient’s initial presentation.

Catherine Callaghan Coombs, MD, discusses 2 upcoming trials in chronic lymphocytic leukemia.